If you're having trouble refilling compounded tirzepatide through Hims, it's very likely a regulatory issue, not a shipping delay — Hims discontinued its compounded semaglutide sales following FDA action, and compounded tirzepatide access has tightened industry-wide.
If your refill has stalled, compounded tirzepatide through a licensed 503A pharmacy remains a legal option for patients with a valid, individualized prescription.
If you've tried to refill compounded tirzepatide through Hims recently and hit a wall, you're not imagining it, and it's very unlikely to be a simple shipping hiccup. This traces back to a significant regulatory shift that reshaped the entire compounded GLP-1 telehealth industry, not just Hims specifically.
What Actually Happened
The FDA determined the tirzepatide shortage resolved in December 2024, followed by semaglutide in February 2025. Once a drug is off the FDA's shortage list, the legal basis that allowed widespread "essentially a copy" compounding during the shortage no longer applies to routine, cost-driven compounding — ongoing 503A compounding is limited to situations with documented individual clinical justification (such as an allergy to an inactive ingredient in the brand product), not simply lower cost or convenience. Following this shift, Hims & Hers discontinued its compounded semaglutide sales, and its compounding pharmacy partner ceased production of these medications. The regulatory pressure has continued into 2026: the FDA proposed on April 30, 2026 to permanently remove semaglutide, tirzepatide, and liraglutide from the list of substances outsourcing facilities may compound in bulk, with the agency stating it found no clinical need for that broader compounding pathway.
This regulatory sequence is worth understanding in its full context, since it explains why the change happened relatively abruptly from a patient's perspective, even though it reflects a gradual, publicly documented regulatory process that had been building for well over a year. The FDA's stated rationale throughout has centered on patient safety concerns tied to less rigorous quality oversight of bulk 503B compounding specifically, as distinct from patient-specific 503A compounding, which remains available under narrower, documented circumstances.
It's also worth noting that Hims specifically reached a settlement with Novo Nordisk that shifted the company's business model toward becoming an authorized distributor of Novo Nordisk's branded products rather than continuing to compound semaglutide independently, which is a distinct business decision layered on top of the broader regulatory shortage-resolution changes affecting the entire compounding industry as a whole.
Why This Shows Up as a "Refill Problem"
For patients already on a compounded tirzepatide subscription, this regulatory shift often shows up as a refill that simply doesn't process, a notice that the specific product is no longer available, or a provider recommending a switch to a different option — rather than an explicit explanation of the underlying regulatory cause. It's worth understanding that this is an industry-wide compliance issue tied directly to the shortage resolution, not a quality or service failure specific to one company.
This distinction matters for how you interpret the experience: if you assume a stalled refill reflects poor service from a specific provider, you might switch providers expecting a different outcome, only to encounter the same underlying regulatory limitation elsewhere. Understanding that this is a market-wide shift, not a company-specific failure, helps you make a more informed decision about what your realistic options actually are going forward.
Some patients report receiving little to no advance notice before a refill simply fails to process, which understandably feels abrupt and can disrupt an established treatment routine without warning. If this happens to you, reaching out to your provider promptly, rather than waiting to see if the issue resolves on its own, is the fastest way to understand your specific situation and available next steps. Waiting too long before reaching out can also mean a longer gap in your treatment, since sourcing a new provider and completing a fresh medical evaluation takes some lead time of its own, separate from whatever caused the original disruption.
A Timeline of How This Unfolded
Understanding the sequence of events helps explain why this change may have felt sudden even though it reflects a gradually developing regulatory situation. The FDA declared the tirzepatide shortage resolved in December 2024, with semaglutide following in February 2025. Hims & Hers reached a settlement with Novo Nordisk in early 2026 that shifted the company toward distributing Novo Nordisk's branded semaglutide products rather than compounded versions, and its compounding pharmacy partner separately stopped production around the same period. The FDA's April 2026 proposal to remove these substances from the bulk 503B compounding list represents a further, additional regulatory step beyond the initial shortage-resolution changes.
Each of these events built on the ones before it, progressively narrowing the legal and practical landscape for cost-driven compounding of these specific medications, which is why patients who'd been on a stable compounded regimen for a year or more may have experienced multiple disruptions across this period rather than a single clean transition. Understanding this layered sequence can help explain why a provider's messaging about the change may have felt inconsistent or incomplete at different points, since the underlying regulatory picture itself was shifting incrementally rather than changing all at once in a single clear announcement.
Compounded tirzepatide remains legally available in 2026 through licensed 503A pharmacies when there's a genuine, documented individual clinical justification for compounding rather than using the commercially available product — not merely as a lower-cost substitute. Any provider offering compounded tirzepatide should be transparent about the clinical basis for your specific prescription, and about which licensed pharmacy is preparing it.
What to Verify If You Switch Providers
If you decide to move to a new compounded tirzepatide provider following a Hims refill disruption, take a few minutes to verify their current standing rather than assuming any provider still offering compounded tirzepatide is automatically operating within the narrower post-shortage rules. Ask directly what clinical basis they document for prescribing compounded rather than brand-name tirzepatide, and confirm the specific compounding pharmacy's state license independently through that state's board of pharmacy website, rather than relying solely on the provider's own claims.
This verification step matters more now than it might have a year or two ago, specifically because the regulatory landscape has tightened considerably, and a provider that was operating within the rules during the shortage period may not have updated its practices to reflect the narrower post-shortage compounding standard, whether due to oversight, delayed compliance updates, or a deliberate choice to continue operating in a legally ambiguous space regardless of the current regulatory environment.
Your Options If Your Refill Has Stalled
Contact your provider directly and ask specifically whether the issue is a supply/regulatory change rather than a shipping delay — that distinction determines what your realistic next steps are. If compounded tirzepatide is genuinely no longer available to you, options include: brand-name Zepbound or Mounjaro through insurance or manufacturer self-pay programs (LillyDirect vials commonly run $299-$449/month depending on dose), or discussing with a new provider whether an individualized clinical justification for continued compounding applies to your specific situation.
A flat-rate compounded provider that documents an appropriate clinical basis for each prescription remains a legitimate option in this landscape. Luma Health's compounded tirzepatide is $297/month, flat, prepared by VialsRx, a 503A pharmacy licensed by the Texas State Board of Pharmacy (license #35264), verifiable directly at pharmacy.texas.gov.
Whichever path you choose, avoid making a decision purely based on the lowest advertised price without confirming the provider's current compliance posture, since the regulatory environment for compounded GLP-1s has genuinely changed and a provider that hasn't adjusted its practices accordingly may be operating outside current rules, regardless of how established or well-known that provider's brand name happens to be in the broader market.
What to Do Next
Whichever path you choose, the most important step is understanding that this is a regulatory shift affecting the industry broadly, not a service failure specific to Hims, and verifying any new provider's current compliance rather than assuming compounded availability elsewhere means a different set of rules applies. Patients who take the time to verify a new provider's licensing and clinical justification practices carefully tend to have a more stable, predictable experience going forward than those who simply chase the lowest advertised price without that verification step.
- Ask your current provider directly whether this is a supply/regulatory issue
- Don't wait too long before exploring alternatives to avoid a treatment gap
- Consider brand-name self-pay pricing as a bridge if needed
- What's the clinical basis for compounding rather than using the commercial product?
- Which licensed pharmacy prepares the medication, and is it verifiable?
- How stable has their supply been through recent regulatory changes?
Questions about your
current treatment options?
Luma Health's providers can evaluate your situation and discuss appropriate options, including compounded tirzepatide at $297/month where clinically appropriate.
Get Started → Or start your free health assessmentFrequently Asked Questions
Most likely because the FDA resolved the tirzepatide shortage in December 2024, which removed the legal basis for widespread cost-driven compounding. Several telehealth providers, including Hims, subsequently discontinued compounded GLP-1 sales.
Yes, but only through licensed 503A pharmacies with a genuine, documented individual clinical justification for compounding rather than using the commercially available product — not simply as a lower-cost substitute.
The FDA proposed removing semaglutide, tirzepatide, and liraglutide from the list of substances that outsourcing facilities (503B) can compound in bulk, stating it found no clinical need for that pathway. This is a separate, additional regulatory action beyond the shortage resolution.
Brand-name Zepbound or Mounjaro through insurance or manufacturer self-pay (LillyDirect vials commonly $299-$449/month by dose), or discussing with a provider whether a documented individual clinical justification applies to your situation.
Industry-wide. The shortage resolution and subsequent FDA enforcement actions affected compounding pharmacies and telehealth providers broadly, not one company specifically.
Ask directly what the documented clinical justification is for compounding in your specific case, and verify the pharmacy's state board license independently. A provider unwilling to answer either question is a red flag.
Possibly. The FDA's April 2026 proposal to remove these substances from the 503B bulk compounding list, if finalized, would further narrow the legal compounding landscape industry-wide, beyond the shortage-resolution changes already in effect.
This depends on your insurance coverage and budget. Brand-name self-pay pricing is meaningfully higher than compounded pricing, so compare your actual expected costs before deciding which path fits your situation.
Reports vary, with some patients describing limited advance notice. If your refill stalls unexpectedly, contact your provider promptly rather than waiting, since sourcing a new provider and evaluation takes some additional lead time.
Yes. Both medications were affected by their respective shortage resolutions (tirzepatide December 2024, semaglutide February 2025), and both are subject to the FDA's April 2026 bulk compounding proposal.
References
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA.gov. 2025. FDA.gov
- U.S. Food and Drug Administration. Human Drug Compounding and the FD&C Act. FDA.gov. FDA.gov
- GoodRx. The Tirzepatide Shortage Is Over: Here's What You Need to Know. GoodRx.com. 2026. GoodRx.com
- U.S. Food and Drug Administration. Prescribing Information for Zepbound (tirzepatide) and Mounjaro (tirzepatide). FDA.gov. 2025. FDA Drug Approvals Database